Trial · NCT02154529
Adverse events450
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 450
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | 3 | 4 | |
| other | Diarrhea | Gastrointestinal disorders | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | 2 | 3 | |
| other | Diarrhea | Gastrointestinal disorders | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | 7 | 8 | |
| other | Diarrhea | Gastrointestinal disorders | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | 2 | 2 | |
| other | Diarrhea | Gastrointestinal disorders | All Patients | 14 | 17 | |
| other | Nausea | Gastrointestinal disorders | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 4 | |
| other | Nausea | Gastrointestinal disorders | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | 2 | 3 | |
| other | Nausea | Gastrointestinal disorders | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | 3 | 8 | |
| other | Nausea | Gastrointestinal disorders | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 2 | |
| other | Nausea | Gastrointestinal disorders | All Patients | 7 | 17 | |
| other | Vomiting | Gastrointestinal disorders | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 4 | |
| other | Vomiting | Gastrointestinal disorders | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 3 | |
| other | Vomiting | Gastrointestinal disorders | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 8 | |
| other | Vomiting | Gastrointestinal disorders | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | 2 | 2 | |
| other | Vomiting | Gastrointestinal disorders | All Patients | 5 | 17 | |
| other | Constipation | Gastrointestinal disorders | Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 4 | |
| other | Constipation | Gastrointestinal disorders | Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV | 1 | 3 | |
| other | Constipation | Gastrointestinal disorders | Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV | 0 | 8 | |
| other | Constipation | Gastrointestinal disorders | Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV | 0 | 2 | |
| other | Constipation | Gastrointestinal disorders | All Patients | 2 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02154529/events